This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CureVac (CVAC) Aandelenoverzicht
CureVac N.V., een biofarmaceutisch bedrijf, richt zich op de ontwikkeling van verschillende transformatieve geneesmiddelen op basis van boodschapperribonucleïnezuur (mRNA). Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
CVAC Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CureVac N.V. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.13 |
| 52 Week Hoogtepunt | US$5.72 |
| 52 Week Laag | US$2.48 |
| Bèta | 1.77 |
| 1 maand verandering | -21.78% |
| 3 maanden verandering | -22.80% |
| 1 Jaar Verandering | 50.18% |
| 3 jaar verandering | -38.17% |
| 5 jaar verandering | -95.92% |
| Verandering sinds IPO | -92.61% |
Recent nieuws en updates
Recent updates
Analyseartikel • Jun 15
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, CureVac N.V. ( NASDAQ:CVAC ) shares have been powering on, with a gain of 50% in the...Analyseartikel • May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
CureVac N.V. ( NASDAQ:CVAC ) recently posted some strong earnings, and the market responded positively. We did some...
Nieuw narratief • May 06
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.Analyseartikel • May 01
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
Those holding CureVac N.V. ( NASDAQ:CVAC ) shares would be relieved that the share price has rebounded 31% in the last...Seeking Alpha • Mar 28
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Summary CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028. CVAC stock received a boost yesterday after winning a key patent dispute against BioNTech, potentially leading to significant damages if infringement is confirmed in 2025. Despite the legal win, CureVac's pipeline remains weak, with only one wholly-owned asset in clinical development, raising concerns about its long-term viability. Upgrading CureVac stock from "Sell" to "Hold" due to the potential financial windfall from the patent dispute, though fundamental issues remain unresolved. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Summary CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025. Financially strong, with $208.8M in cash plus additional funds of $412.53M from GlaxoSmithKline agreement being redone; the Company believes that it has enough cash on hand to fund operations into 2028. Read the full article on Seeking AlphaAnalyseartikel • Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
CureVac N.V. ( NASDAQ:CVAC ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Seeking Alpha • Oct 08
CureVac: Back To Square One
Summary Today, we're circling back to a development company called CureVac N.V. The company recently agreed to a deal with GSK plc, that involved a huge upfront payment, as well as potential milestone payouts and royalties. That left CureVac with a huge amount of cash on its balance sheet but pushed its pipeline back to very early-stage development. Read the full article on Seeking AlphaAnalyseartikel • Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
It's not a stretch to say that CureVac N.V.'s ( NASDAQ:CVAC ) price-to-sales (or "P/S") ratio of 10.6x right now seems...Analyseartikel • Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Key Insights The projected fair value for CureVac is US$6.64 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Jul 04
CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Summary CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. The mRNA specialist was unable to develop a successful COVID vaccine, unlike rivals Moderna and BioNTech. GSK's $400m purchase of CureVac's infectious disease vaccine candidates, announced yesterday, provides a financial lifeline with milestones, and royalties pledged >$1bn. Despite the deal, CureVac still faces challenges in catching up to competitors like Moderna and BioNTech, making a "sell" recommendation appropriate at this time, in my view. Read the full article on Seeking AlphaAnalyseartikel • Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
CureVac N.V. ( NASDAQ:CVAC ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Mar 08
CureVac: No Momentum In Sight
Summary CureVac faces challenges as a German court invalidates one of their key mRNA technology patents, raising concerns about their ability to compete in the mRNA space. The invalidated patent relates to an invention that many argue was not a genuine "invention" as the concepts and technologies were already well-known in the scientific community. CureVac's future prospects rely heavily on their partnerships, such as their joint effort with GSK for influenza and COVID vaccines, and their RNA Printer technology for point-of-care production of RNA therapeutics. Read the full article on Seeking AlphaAnalyseartikel • Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...Analyseartikel • Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Key Insights The projected fair value for CureVac is US$19.46 based on 2 Stage Free Cash Flow to Equity CureVac is...Analyseartikel • May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
The latest analyst coverage could presage a bad day for CureVac N.V. ( NASDAQ:CVAC ), with the analysts making...Analyseartikel • Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
The analysts might have been a bit too bullish on CureVac N.V. ( NASDAQ:CVAC ), given that the company fell short of...Analyseartikel • Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Key Insights CureVac's estimated fair value is €15.4 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Aug 18
CureVac BV reports Q2 results
CureVac BV press release (NASDAQ:CVAC): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program Shares +1.37% PM.Seeking Alpha • Jul 05
CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE). The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it would fair compensation for the alleged violations. While CureVac (CVAC) has added ~1%, both BioNTech (BNTX) and Pfizer (PFE) have lost ~1% in the pre-market so far. However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine. The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine.Analyseartikel • May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
Celebrations may be in order for CureVac N.V. ( NASDAQ:CVAC ) shareholders, with the analysts delivering a significant...Analyseartikel • Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Seeking Alpha • Sep 01
CureVac: Wait For Concrete News Before Investing
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.Analyseartikel • Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Rendement voor aandeelhouders
| CVAC | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -19.2% | 1.2% | 1.1% |
| 1Y | 50.2% | 34.6% | 28.7% |
Rendement versus industrie: CVAC overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 34.6 % opleverde.
Rendement versus markt: CVAC overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.
Prijsvolatiliteit
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: CVAC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van CVAC is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2000 | 904 | Alexander Zehnder | www.curevac.com |
CureVac N.V., een biofarmaceutisch bedrijf, richt zich op de ontwikkeling van verschillende transformatieve geneesmiddelen op basis van boodschapperribonucleïnezuur (mRNA). Het portfolio van het bedrijf omvat klinische en preklinische kandidaten voor verschillende ziekte-indicaties in profylactische vaccins, oncologie en moleculaire therapie. Het bedrijf levert ook geoptimaliseerde mRNA's om de productie van therapeutische eiwitten te stimuleren met behulp van zijn technologie en instrueert menselijke cellen om specifieke eiwitten te produceren of uit te scheiden in de kern, het cytoplasma, de celorganellen en het celmembraan.
CureVac N.V. Samenvatting
| CVAC fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.09b |
| Inkomsten(TTM) | US$151.26m |
| Inkomsten(TTM) | US$83.06m |
6.1x
Koers/Winstverhouding11.2x
P/S-verhoudingIs CVAC overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CVAC resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €70.74m |
| Kosten van inkomsten | €4.75m |
| Brutowinst | €65.99m |
| Overige uitgaven | -€62.83m |
| Inkomsten | €128.82m |
Laatst gerapporteerde inkomsten
Sep 30, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.57 |
| Brutomarge | 93.29% |
| Nettowinstmarge | 182.11% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CVAC op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2025/12/17 12:55 |
| Aandelenkoers aan het einde van de dag | 2025/12/17 00:00 |
| Inkomsten | 2025/09/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CureVac N.V. wordt gevolgd door 4 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Eun Kyung Yang | Jefferies LLC |
| Roger Song | Jefferies LLC |